Data on neuraminidase inhibitors were made availableBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7438.523-a (Published 26 February 2004) Cite this as: BMJ 2004;328:523
All rapid responses
EDITOR- In response to Symmonds et al, Panahloo stated that he
planned to publish the results from studies WV15759/WV15871. But I still
cannot find the published data.
I agree Symmonds, because I also confirmed the same data of
WV15759/WV15871 in the Japanese new drug approval package (NAP) of
oseltmivir dry syrup .
According to the figure of Kaplan-Meier curve for proportion of
patients without freedom from illness in the Japanese NAP, apparently non-
significant earlier time to freedom from illness in children receiving
oseltamivir than those receiving placebo is shown until around the median
time to freedom from illness.
However after about 70 percent of the children receiving placebo became
free from illness, children receiving placebo seem becoming free from
illness earlier than those receiving oseltamivir. Thus the average
duration of illness is 14.7 hours less in placebo group than in
oseltamivir group (mean +- standard deviation: 167.9+-11.7 vs 182.6 +-
15.9 hrs respectively; p value is not stated).
How could it be explained? Isn't this controversial phenomenon
related to the development of resistance? 
I hope data become published as soon as possible so that we could
know the full profile of harm and benefit.
HAMA, Rokuro MD
Japan Institute of Pharmacovigilance. Tennoji-ku Osaka, Japan
1. Symmonds M, Matheson NJ, Harnden A. Guidelines on neuraminidase
inhibitors in children are not supported by evidence. BMJ. 2004 Jan 24;
2. Panahloo Z. Data on neuraminidase inhibitors were made available.
BMJ. 2004 Feb 28;328(7438):523.
3. New drug approval package (NAP) of oseltmivir (in Japanese);
Tamiflu dry syrup (2002):
4. Kiso M, Mitamura K,Kawaoka Y. et al. Resistant influenza A viruses
in children treated with oseltamivir: descriptive study. Lancet. 2004 Aug
Competing interests: No competing interests